These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8415770)

  • 1. Orally administered interferons suppress bone marrow function.
    Koren S; Fleischmann WR
    Proc Soc Exp Biol Med; 1993 Nov; 204(2):155-64. PubMed ID: 8415770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orally administered interferons exert their white blood cell suppressive effects via a novel mechanism.
    Fleischmann WR; Koren S; Fleischmann CM
    Proc Soc Exp Biol Med; 1992 Nov; 201(2):200-7. PubMed ID: 1384066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic effects of orally administered interferons and interleukin-2.
    Fleischmann WR; Koren S
    J Interferon Cytokine Res; 1999 Aug; 19(8):829-39. PubMed ID: 10476926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian variations in myelosuppressive activity of interferon-alpha in mice: identification of an optimal treatment time associated with reduced myelosuppressive activity.
    Koren S; Fleischmann WR
    Exp Hematol; 1993 Apr; 21(4):552-9. PubMed ID: 8462664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of mice with macrophage colony stimulating factor (CSF-1) prevents the in vivo myelosuppression induced by murine alpha, beta, and gamma interferons.
    Koren S; Klimpel GR; Fleischmann WR
    J Biol Response Mod; 1986 Oct; 5(5):481-9. PubMed ID: 3095498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of peripheral leukocyte counts in mice by oral administration of interferons.
    Fleischmann WR; Fields EE; Wang JL; Hughes TK; Stanton GJ
    Proc Soc Exp Biol Med; 1991 Sep; 197(4):424-30. PubMed ID: 1714606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal circadian timing reduces the myelosuppressive activity of recombinant murine interferon-gamma administered to mice.
    Koren S; Fleischmann WR
    J Interferon Res; 1993 Jun; 13(3):187-95. PubMed ID: 8366285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of peripheral leukocyte counts and bone marrow function in mice by oral administration of interleukin-2.
    Koren S; Fleischmann WR
    J Interferon Res; 1994 Dec; 14(6):343-7. PubMed ID: 7897253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macrophage colony stimulating factor (CSF-1) blocks the myeloid suppressive but not the antiviral or antiproliferative activities of murine alpha, beta, and gamma interferons in vitro.
    Koren S; Klimpel GR; Fleischmann WR
    J Biol Response Mod; 1986 Dec; 5(6):571-80. PubMed ID: 2432191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 inhibits in vitro granulocyte-macrophage colony formation.
    Naldini A; Fleischmann WR; Ballas ZK; Klimpel KD; Klimpel GR
    J Immunol; 1987 Sep; 139(6):1880-4. PubMed ID: 2442258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice.
    Bohoslawec O; Trown PW; Wills RJ
    J Interferon Res; 1986 Jun; 6(3):207-13. PubMed ID: 3745986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gamma interferon (IFN gamma) and IFN alpha/beta suppress murine myeloid colony formation (CFU-C)N: magnitude of suppression is dependent upon level of colony-stimulating factor (CSF).
    Klimpel GR; Fleischmann WR; Klimpel KD
    J Immunol; 1982 Jul; 129(1):76-80. PubMed ID: 6177763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of recombinant interferons with recombinant interleukin-2: differential effects on natural killer cell activity and interleukin-2-activated killer cells.
    Brunda MJ; Tarnowski D; Davatelis V
    Int J Cancer; 1986 May; 37(5):787-93. PubMed ID: 2422129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo myelosuppression by combination interferon treatment: antagonism of MuIFN-gamma and MuIFN-beta myelosuppressive effects.
    Naldini A; Fleischmann WR
    J Biol Response Mod; 1987 Oct; 6(5):546-55. PubMed ID: 3119781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of release of granulocyte- and granulocyte-macrophage colony-stimulating factors from phytohemagglutinin-stimulated sorted subsets of human T lymphocytes by recombinant human tumor necrosis factor-alpha. Synergism with recombinant human IFN-gamma.
    Lu L; Srour EF; Warren DJ; Walker D; Graham CD; Walker EB; Jansen J; Broxmeyer HE
    J Immunol; 1988 Jul; 141(1):201-7. PubMed ID: 2454257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity.
    Leonard JP; Neben TY; Kozitza MK; Quinto CM; Goldman SJ
    Exp Hematol; 1996 Feb; 24(2):270-6. PubMed ID: 8641352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human interferon-alpha A/D enhances the expression of Ly-6A/E, Ly-6C, and TAP antigens on murine T lymphocytes.
    Dumont FJ
    J Interferon Res; 1988 Jun; 8(3):347-56. PubMed ID: 2842413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mast cell growth factor (C-kit ligand) in combination with granulocyte-macrophage colony-stimulating factor and interleukin-3: in vivo hemopoietic effects in irradiated mice compared to in vitro effects.
    Patchen ML; Fischer R; MacVittie TJ; Seiler FR; Williams DE
    Biotherapy; 1993; 7(1):13-26. PubMed ID: 7520725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian dependence of interferon antitumor activity in mice.
    Koren S; Whorton EB; Fleischmann WR
    J Natl Cancer Inst; 1993 Dec; 85(23):1927-32. PubMed ID: 8230283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Organ-specific hematopoietic changes induced by a recombinant human interferon-alpha in mice.
    Rosenthal GJ; Stranahan RP; Thompson M; Blair P; Germolec DR; Comment CE; Schwab K; Luster MI
    Fundam Appl Toxicol; 1990 May; 14(4):666-75. PubMed ID: 2361570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.